RMX Industries has deployed its QuantrusX™ edge intelligence platform commercially since June at a Texas elite training facility, providing real-time, on-site perimeter and ground monitoring without relying on centralized data centers. This deployment ensures the facility retains full control over its data and receives reliable, actionable intelligence. Following this, RMX secured a deployment agreement for a multi-use house of worship in Austin and published research on Real-World Intelligence, highlighting its focus on physical-edge data solutions. The company aims to maintain high operational standards as it expands its technology applications.
RMX Industries and its QuantrusX platform are the subject of this update, provided here with Pluang's Technology sector market data for context. Of 150 priced US Technology stocks on Pluang, 66 rose and 82 fell today. Notable price changes include GoPro Inc (GPRO) at USD 1.29 with a -4.44% change, TeraWulf Inc (WULF) at USD 14.80 down 4.33%, and Corsair Gaming Inc (CRSR) at USD 13.57 up 4.14%, as of Sep 15, 2026 23:03 WIB.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
